Detecting temporal lobe seizures in ultra long-term subcutaneous EEG using algorithm-based data reduction.
Line S Remvig, Jonas Duun-Henriksen, Franz Fürbass...
https://pubmed.ncbi.nlm.nih.gov/35987094/Actively Recruiting
Led by Azienda Ospedaliero-Universitaria di Modena · Updated on 2025-03-04
30
Participants Needed
4
Research Sites
30 weeks
Total Duration
Researchers are studying patients with drug-resistant epilepsies, developmental and epileptic encephalopathies DEE, or rare epilepsies to develop a personalized care model using a minimally invasive, wearable, subcutaneous EEG device sqEEG for ultra-long-term monitoring at home. The study aims to assess the devices ability to reliably detect seizures over extended periods, verify automated seizure detection algorithms, and evaluate how the collected data may improve clinical management and treatment outcomes. This approach hopes to reduce hospitalization side effects and provide accurate seizure quantification in real-life settings to enhance quality of life. The study involves two parts an initial short-term inpatient phase where subcutaneous EEG electrodes are implanted by a neurosurgeon and tested alongside standard video-EEG monitoring in an Epilepsy Monitoring Unit. This phase evaluates the devices safety, sensitivity, tolerability, and algorithm accuracy. The second, core part consists of home-based monitoring using the wearable device for at least 12 weeks, with an optional extension up to 24 weeks if deemed beneficial. Participants continue their usual anti-seizure medication adjustments during this time, while device usage and adverse effects are closely tracked. Participants will document seizure events in diaries, supported by caregivers if needed, while weekly reviews of EEG data and safety assessments occur. The study team will compare seizure reports from the device, diaries, and clinical evaluations to determine accuracy and potential impact on patient care. After the home monitoring period, the implanted electrode is removed, and a follow-up visit is planned. Data collected will assess device safety, seizure detection accuracy, and the clinical usefulness of long-term EEG monitoring in managing epilepsy.
CONDITIONS
Home Ultra-long Term EEG Monitoring for Rare Epilepsies and Developmental and Epileptic Encephalopathies
S
Stefania Maffei, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Azienda Ospedaliero-Universitaria di Modena
Lead Sponsor
Azienda Ospedaliera Universitaria Federico II (AOU Federico II)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for recruitment and consent
Duration - Single day procedure with recovery
Participants undergo implantation of subcutaneous EEG electrodes by a surgeon or neurosurgeon under local anesthesia to place electrode contacts over the seizure focus.
1 visit for implantation surgery
Duration - 2 days to 2 weeks
Participants are admitted to the Epilepsy Monitoring Unit (EMU) for 2 days up to 2 weeks to record seizures using video-EEG and subcutaneous EEG (sqEEG), testing the sensitivity, safety, and tolerability of the device in a clinical setting.
Continuous monitoring during EMU admission
Duration - At least 12 weeks, up to 24 weeks
Participants are discharged home with the implanted device for ultra-longterm EEG monitoring to assess seizure detection sensitivity, device tolerability, and safety in their daily environment.
Weekly visits for device assessment and data collection
Duration - Post-monitoring period following device removal
After home monitoring, participants have the subscalp electrode removed and a follow-up visit is planned according to clinical practice.
1 visit for device removal and follow-up
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Line S Remvig, Jonas Duun-Henriksen, Franz Fürbass...
https://pubmed.ncbi.nlm.nih.gov/35987094/Barbara Blachut, Christian Hoppe, Rainer Surges...
https://pubmed.ncbi.nlm.nih.gov/28139449/Pedro F Viana, Line S Remvig, Jonas Duun-Henriksen...
https://pubmed.ncbi.nlm.nih.gov/34250608/Pedro F Viana, Jonas Duun-Henriksen, Martin Glasstëter...
https://pubmed.ncbi.nlm.nih.gov/33275838/Troels W Kjaer, Line S Remvig, Asbjoern W Helge...
https://pubmed.ncbi.nlm.nih.gov/35002910/Marina Trivisano, Nicola Specchio
https://pubmed.ncbi.nlm.nih.gov/32049741/Annelieke R Müller, Marion M M G Brands, Peter M van de Ven...
https://pubmed.ncbi.nlm.nih.gov/33504638/Mark J Cook, Terence J O'Brien, Samuel F Berkovic...
https://pubmed.ncbi.nlm.nih.gov/23642342/Christian E Elger, Christian Hoppe
https://pubmed.ncbi.nlm.nih.gov/29452687/Sigge Weisdorf, Sirin W Gangstad, Jonas Duun-Henriksen...
https://pubmed.ncbi.nlm.nih.gov/29995605/Azienda Ospedaliero-Universitaria di Modena
Lead Sponsor
Azienda Ospedaliera Universitaria Federico II (AOU Federico II)
Collaborating Sponsor